- ACC Expert Consensus Decision Pathway
- angiotensin receptor-neprilysin inhibitors
- beta blockers
- guideline-directed medical therapy
- heart failure
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure : A Report of the American College of Cardiology Solution Set Oversight Committee. / Hollenberg, Steven M.; Warner Stevenson, Lynne; Ahmad, Tariq; Amin, Vaibhav J.; Bozkurt, Biykem; Butler, Javed; Davis, Leslie L.; Drazner, Mark H.; Kirkpatrick, James N.; Peterson, Pamela N.; Reed, Brent N.; Roy, Christopher L.; Storrow, Alan B.In: Journal of the American College of Cardiology, Vol. 74, No. 15, 15.10.2019, p. 1966-2011.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure
T2 - A Report of the American College of Cardiology Solution Set Oversight Committee
AU - Hollenberg, Steven M.
AU - Warner Stevenson, Lynne
AU - Ahmad, Tariq
AU - Amin, Vaibhav J.
AU - Bozkurt, Biykem
AU - Butler, Javed
AU - Davis, Leslie L.
AU - Drazner, Mark H.
AU - Kirkpatrick, James N.
AU - Peterson, Pamela N.
AU - Reed, Brent N.
AU - Roy, Christopher L.
AU - Storrow, Alan B.
N1 - Funding Information: The work of the writing committee was supported exclusively by the ACC Foundation without commercial support. Writing committee members volunteered their time to this effort. All members of the writing committee, as well as those selected to serve as peer reviewers of this document, were required to disclose relationships with industry (RWI) and other entities (See Appendixes 1 and 2 , respectively). The Chair is without any RWI and is responsible for the content of this document. In keeping with ACC policy, the majority of the writing committee were without relevant RWI. The formal peer review process was completed consistent with ACC policy, and included a public comment period to obtain further feedback. Following reconciliation of all comments, this document was approved for publication by the Clinical Policy Approval Committee.
PY - 2019/10/15
Y1 - 2019/10/15
KW - ACC Expert Consensus Decision Pathway
KW - CHF
KW - angiotensin receptor-neprilysin inhibitors
KW - beta blockers
KW - comorbidities
KW - diuretics
KW - guideline-directed medical therapy
KW - heart failure
UR - http://www.scopus.com/inward/record.url?scp=85072648736&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072648736&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2019.08.001
DO - 10.1016/j.jacc.2019.08.001
M3 - Article
C2 - 31526538
AN - SCOPUS:85072648736
VL - 74
SP - 1966
EP - 2011
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
SN - 0735-1097
IS - 15